C12N 2760/20241
Use of virus, viral particle or viral elements as a vector
C12N2760/20241 (Use of virus, viral particle or viral elements as a vector) appears on 114 US grants and 238 published applications in this corpus.
Search patents in C12N- Granted patents
- 114
- Published applications
- 238
- Assignees
- 100
- Inventors
- 376
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 5 |
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 1 | 2 |
| 2007 | 0 | 6 |
| 2008 | 1 | 2 |
| 2009 | 1 | 1 |
| 2010 | 2 | 7 |
| 2011 | 5 | 6 |
| 2012 | 4 | 7 |
| 2013 | 1 | 6 |
| 2014 | 2 | 10 |
| 2015 | 1 | 2 |
| 2016 | 5 | 6 |
| 2017 | 11 | 18 |
| 2018 | 8 | 5 |
| 2019 | 10 | 19 |
| 2020 | 8 | 10 |
| 2021 | 6 | 17 |
| 2022 | 5 | 13 |
| 2023 | 7 | 21 |
| 2024 | 6 | 38 |
| 2025 | 17 | 19 |
| 2026 | 9 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/20243Viral genome or elements thereof as genetic vectorIndexing code93
- C12N 2760/20245Special targeting system for viral vectorsIndexing code18
- C12N 2760/20244Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code5
- C12N 2760/20242Virus or viral particle as vehicleIndexing code4
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods and materials for treating cancer4 Aug 2026US 12,697,361 B2Mayo Foundation for Medical Education and Research
- VSV rescue7 Jul 2026US 12,674,143 B2Boehringer Ingelheim International GmbH
- Coronavirus pseudovirus packaging system, packaging method therefor, and application of coronavirus pseudovirus in evaluating disinfection efficacy14 Apr 2026US 12,600,988 B2Fantasia Biopharma (Zhejiang) Co. Ltd
- In vivo daric17 Sep 2026US 2026/0273058 A1Kelonia Therapeutics, Inc.
- Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells of the peripheral nervous system27 Aug 2026US 2026/0248957 A1Turn Biotechnologies, Inc.
- Transduction aids and transduction methods27 Aug 2026US 2026/0250635 A1
- Mutant vsvg and targeting vector13 Aug 2026US 2026/0234198 A1Shenzhen Genocury Biotech Co., Ltd.
- Targeting vector, preparation method therefor and use thereof21 May 2026US 2026/0137811 A1Shenzhen Genocury Biotech Co., Ltd.
Most cited
By later US patents
- cDNA corresponding to the antigenome of nonsegmented negative stranded RNA viruses and process for the production of such viruses40US 7,993,924 B2Crucell Switzerland AG · 2011
- Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof29US 6,136,585 AThe UAB Research Foundation · 2000
- Compositions and methods for treatment of cytomegalovirus20US 9,777,043 B2Variation Biotechnologies Inc. · 2017
- Recombinant Rhabdovirus containing a heterologous fusion protein16US 6,497,873 B1The University of Tennessee Research Corporation · 2002
- Glucagon-like-peptide-2 (GLP-2) analogues14US 7,563,770 B2Zealand Pharma A/S · 2009